NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies

Key Takeaways NVO expanded its partnership with Aspect to develop potentially curative cell therapies for diabetes.Aspect will lead development and manufacturing, while NVO keeps options for later-stage involvement.The deal adds equity funding, milestones and royalties, giving NVO long-term upside if therapies succeed.Novo Nordisk (NVO) and Aspect Biosystems announced that they are advancing their partnership into a new phase focused on developing next-generation cellular medicines for diabetes.The companie ...